| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Certepetide | CEND-1; iRGD; CIND-1; LSTA1; QLC12102; LSTA-1 | Phase 2 Clinical | Drugcendr Inc | Appendiceal Neoplasms; Bile Duct Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Triple Negative Breast Neoplasms | Details |